메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

ACTIVE 2.0 Project Launches in Malaysia to Improve Cervical Cancer Treatment

KUALA LUMPUR, Malaysia, July 16, 2025 -- A regional effort to improve cervical cancer care for patients has launched in Malaysia. Involving 6 countries in Southeast Asia, Project ACTIVE 2.0 aims to enhance cervical cancer treatment and support patient recovery across Southeast Asia. The three-year initiative will focus on strengthening healthcare systems through clinical training, infrastructure upgrades, and digital innovations, with the goal of expanding access to high-quality, targeted cervical cancer care for patients and their families. Cervical cancer remains a significan
- 김갑성 기자
- 2025-07-16 16:14
Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac Microcurrent Therapy in ESC Heart Failure

Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 -- Berlin Heals, a pioneer in bioelectric medicine for the treatment of heart failure, is pleased to announce the publication of a new peer-reviewed study titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study" in the ESC Heart Failure journal. The study presents the long-term follow-up of patients enrolled in the initial pilot trial of the Cardiac Microcurrent I
- 김갑성 기자
- 2025-07-16 15:00
JETRO and METI Hold First-ever "Global Healthcare Challenge," Featuring International Symposium in Healthcare Sector and Pitch Competition among World's Startups

[ 메디채널 김갑성 기자 ] - AI Medical Service Inc. from Japan Wins Gold Prize - TOKYO, July 16, 2025 -- During the "Health and Well-being" theme week at the Expo 2025 Osaka, Kansai, the Japan External Trade Organization (JETRO) and Japan's Ministry of Economy, Trade and Industry (METI) jointly hosted an international symposium on healthcare and a pitch competition for healthcare startups from around the world, titled the "Global Healthcare Challenge" (GHeC), at the Grand Prince Hotel Osaka Bay on June 25 (Wednesday) and 26 (Thursday), 2025. The event was designed to help J
- 김갑성 기자
- 2025-07-16 14:00
Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 16, 2025 -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U.S. National Cancer Institute (NCI) as part of a five-year cancer research program. The first patient in the monotherapy clinical trial for advanced solid tumors has been successfully enrolled at the NIH Clinical Center in Bethesda, Maryland, USA. The NCI will fund the full cost of the
- 김갑성 기자
- 2025-07-16 10:32
Medley Expands Operations in the Philippines to Accelerate Global Growth

MANILA, Philippines, July 16, 2025 -- Medley (TSE: 4480), a leading Japan-based healthcare technology group, has announced the relocation and expansion of its operational functions in the Philippines to help accelerate the company's global business growth. The new office, located at 32nd Street corner 3rd Avenue, Bonifacio Global City (BGC), Taguig City, offers a sleek, modern space for the company's fast-growing team. It will serve as a key operational hub for Medley's global business and underscores the company's continued commitment to international expansion. Remaining in
- 김갑성 기자
- 2025-07-16 10:17
Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection

TOKYO, July 16, 2025 -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to develop "aiGait" powered by Uvance, a solution that leverages Fujitsu's advanced skeleton recognition AI technology to detect gait pattern abnormalities, and provide gait quantization to healthcare professionals to support the early diagnosis of dementia and Parkinson's disease. The technology is part of "Fujitsu Kozuchi for Vision" from the Fujitsu Uvance offering "AI Technologies and Solutions
- 김갑성 기자
- 2025-07-16 10:04
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 16, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastatic colorectal cancer (mCRC). This randomized, controlled, multi-center Phase III clinical trial for first-line treatment of mCRC is one of the company's key initiatives to address the significant unmet clinical need worldwide with ivonescimab. Colorectal cancer remains the third mo
- 김갑성 기자
- 2025-07-16 09:47
ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included in the PADO-RSV priority list. Ziresovir, developed by Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), is the first and only RSV antiviral drug to be included in the list. This is the first time WHO has included an anti-RSV drug developed from China in the paediatric drug optimizati
- 김갑성 기자
- 2025-07-16 09:00
AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact

- 880 AbbVie employees across 7 markets volunteered over 3,000 hours to support vulnerable groups.- Over 650 individuals benefited from 24 volunteer initiatives, delivered in partnership with 17 community organisations across the region. SINGAPORE, July 16, 2025 -- AbbVie employees in Asia participated in the tenth Week of Possibilities (WOP), the AbbVie Foundation's annual global volunteering programme, held in June and July. This unites our employees around the world with a single purpose to serve our local communities. 880 employees across Singapore
- 황정호 기자
- 2025-07-16 09:00
PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test

FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care by enabling more informed antibiotic use and aiding in the reduction of antimicrobial resistance. Introduction of FebriDx will enhance PHASE Scientific's INDICAID® portfolio and strengthen its leadership in point-of-care respiratory diagnostics. Partnership underscores PHASE Scientific's proven commercial execution in the U.S. market with its extensive nationwide clinical net
- 김갑성 기자
- 2025-07-16 08:54

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2025-09-08_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 08일 19시 00분